Enhancement of bone formation in an experimental bony defect using ferumoxide-labelled mesenchymal stromal cells and a magnetic targeting system

Journal of Bone and Joint Surgery - Series B

Volumn 92 B, Issue 11, 2010, Pages 1606-1613

  Oshima, S ^a,b   Ishikawa, M ^a,b   Mochizuki, Y ^a,c   Kobayashi, T ^a,d   Yasunaga, Y ^a   Ochi, M ^a,b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Department of Orthopaedic Surgery ^*  (Japan)

^c HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

^d MATSUYAMA RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYAPATITE; SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEFECT; CERAMICS; CONTROLLED STUDY; FRACTURE; FRACTURE HEALING; FRACTURE NONUNION; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; RABBIT; STROMA CELL;

ANIMALS; BIOCOMPATIBLE MATERIALS; BONE SUBSTITUTES; CELL CULTURE TECHNIQUES; CELL MOVEMENT; CERAMICS; DEXTRANS; DISEASE MODELS, ANIMAL; DURAPATITE; FRACTURE HEALING; MAGNETICS; MAGNETITE NANOPARTICLES; MESENCHYMAL STEM CELL TRANSPLANTATION; OSTEOGENESIS; RABBITS; STROMAL CELLS; ULNA FRACTURES;

EID: 78649425539     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.92B11.23491     Document Type: Article

References (48)

1. Keating JF, McQueen MM. Substitutes for autologous bone graft in orthopaedic trauma. J Bone Joint Surg [Br] 2001;83-B:3-8.
2. Boden SD. Bone repair and enhancement clinical trial design: spine applications. Clin Orthop 1998;355(Suppl):S336-46.
3. Arrington ED, Smith WJ, Chambers HG, Bucknell AL, Davino NA. Complications of iliac crest bone graft harvesting. Clin Orthop 1996;329:300-9.
4. Banwart JC, Asher MA, Hassanein RS. Iliac crest bone graft harvest donor site morbidity: a statistical evaluation. Spine 1995;20:1055-60.
5. Enneking WF, Campanacci DA. Retrieved human allografts: a clinicopathological study. J Bone Joint Surg [Am] 2001;83-A:971-86.
6. Ito H, Koefoed M, Tiyapatanaputi P, et al. Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med 2005;11:291-7. (Pubitemid 40460557)
7. Borden M, Attawia M, Khand Y, El-Amin SF, Laurencin CT. Tissue-engineered bone formation in vivo using a novel sintered polymeric microsphere matrix. J Bone Joint Surg [Br] 2004;86-B:1200-8.
8. Tamai N, Myoui A, Tomita T, et al. Novel hydroxyapatite ceramics with an interconnective porous structure exhibit superior osteoconduction in vivo. J Biomed Mater Res 2002;59:110-17.
9. Ito Y, Tanaka N, Fujimoto Y, et al. Bone formation using novel interconnected porous calcium hydroxyapatite ceramic hybridized with cultured marrow stromal stem cells derived from Green rat. J Biomed Mater Res A 2004;69:454-61.
10. Tanaka N, Nakanishi K, Fujimoto Y, et al. Expansive laminoplasty for cervical myelopathy with interconnected porous calcium hydroxyapatite ceramic spacers: comparison with autogenous bone spacers. J Spinal Disord Tech 2008;21:547-52.
11. Bruder SP, Kraus KH, Goldberg VM, Kadiyala S. The effect of implants loaded with autologous mesenchymal stem cells on the healing of canine segmental bone defects. J Bone Joint Surg [Am] 1998;80-A:985-96. (Pubitemid 28355669)
12. Wan C, He Q, Li G. Allogenic peripheral blood derived mesenchymal stem cells (MSCs) enhance bone regeneration in rabbit ulna critical-sized bone defect model. J Orthop Res 2006;24:610-18.
13. Louisia S, Stromboni M, Meunier A, Sedel L, Petite H. Coral grafting supplemented with bone marrow. J Bone Joint Surg [Br] 1999;81-B:719-24.
14. Clarke SA, Hoskins NL, Jordan GR, Marsh DR. Healing of an ulnar defect using a proprietary TCP bone graft substitute, JAX, in association with autologous osteogenic cells and growth factors. Bone 2007;40:939-47.
15. Na K, Kim SW, Sun BK, et al. Osteogenic differentiation of rabbit mesenchymal stem cells in thermo-reversible hydrogel constructs containing hydroxyapatite and bone morphogenic protein-2 (BMP-2). Biomaterials 2007;28:2631-7.
16. Cood SD, Baffes GC, Wolfe MW, et al. The effect of recombinant human osteogenic protein-1 on healing of large segmental bone defects. J Bone Joint Surg [Am] 1994;76-A:827-38.
17. Bostrom M, Lane JM, Tomin E, et al. Use of bone morphogenetic protein-2 in the rabbit ulnar nonunion model. Clin Orthop 1996;327:272-82. (Pubitemid 26174996)
18. Kaito T, Myoui A, Takaoka K, et al. Potentiation of the activity of bone morphogenetic protein-2 in bone regeneration by a PLA-PEG/hydroxyapatite composite. Biomaterials 2005;26:73-9.
19. Otsuru S, Tamai K, Yamazaki T, Yoshikawa H, Kaneda Y. Circulating bone marrow- derived osteoblast progenitor cells are recruited to the bone-forming site by the CXCR4/stromal cell-derived factor-1 pathway. Stem Cells 2008;26:223-34.
20. Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP. Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J Cell Biochem 1997;64:295-312. (Pubitemid 27065443)
21. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
22. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71-4.
23. Wakitani S, Saito T, Caplan AI. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve 1995;18:1417-26.
24. Negishi Y, Kudo A, Obinata A, et al. Multipotency of a bone marrow stromal cell line, TBR31-2, established from ts-SV40 T antigen gene transgenic mice. Biochem Biophys Res Commun 2000;268:450-5.
25. Ochi M, Adachi N, Nobuto H, et al. Articular cartilage repair using tissue engineering technique: novel approach with minimally invasive procedure. Artif Organs 2004;28:28-32.
26. Kobayashi T, Ochi M, Yanada S, et al. A novel cell delivery system using magnetically labeled mesenchymal stem cells and an exteral magnetic device for clinical cartilage repair. Arthroscopy 2008;24:69-76.
27. Nishida K, Tanaka N, Nakanishi K, et al. Magnetic targeting of bone marrow stromal cells into spinal cord: through cerebrospinal fluid. Neuroreport 2006;17:1269-72. (Pubitemid 44337064)
28. Arbab AS, Yocum GT, Rad AM, et al. Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells. NMR Biomed 2005;18:553-9.
29. Kostura L, Kraitchman DL, Mackay AM, Pittenger MF, Bulte JW. Feridex labeling of mesenchymal stem cells inhibits chondrogenesis but not adipogenesis or osteogenesis. NMR Biomed 2004;17:513-17.
30. Wang J, Asou Y, Sekiya I, et al. Enhancement of tissue engineered bone formation by a low pressure system improving cell seeding and medium perfusion into a porous scaffold. Biomaterials 2006;27:2738-46.
31. Shimizu K, Ito A, Honda H. Mag-seeding of rat bone marrow stromal cells into porous hydroxyapatite scaffolds for bone tissue engineering. J Biosci Bioneg 2007;104:171-7. (Pubitemid 47615568)
32. Tatebe M, Nakamura R, Kagami H, Okada K, Ueda M. Differentiation of transplanted mesenchymal stem cells in a large osteochondral defect in rabbit. Cytotherapy 2005;7:520-30.
33. Nishimori M, Deie M, Kanaya A, et al. Repair of chronic osteochondral defects in the rat: a bone marrow-stimulating procedure enhanced by cultured allogenic bone marrow mesenchymal stromal cells. J Bone Joint Surg [Br] 2006;88-B:1236-44.
34. Chuang CK, Lin KJ, Lin CY, et al. Xenotransplantation of human mesenchymal stem cells into immunocompetent rats for calvarial bone repair. Tissue Eng Part A 2010;16:479-88.
35. Natsu K, Ochi M, Mochizuki Y, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote the regeneration of injured skeletal muscle without differentiation into myofibers. Tissue Eng 2004;10:1093-112.
36. Winkler T, von Roth P, Schuman MR, et al. In vivo visualization of locally transplanted mesenchymal stem cells in the severely injured muscle in rats. Tissue Eng Part A 2008;14:1149-60. (Pubitemid 351931499)
37. Otsuru S, Tamai K, Yamazaki T, Yoshikawa H, Kaneda Y. Bone marrow-derived osteoblast progenitor cells in circulating blood contribute to ectopic bone formation in mice. Biochem Biophys Res Commun 2007;354:453-8.
38. Francois S, Bensidhoum M, Mouiseddine M, et al. Local irradiation not only induces homing of mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells 2006;24:1020-9.
39. Kotani H, Kawaguchi H, Shimoaka T, et al. Strong static magnetic field stimulates bone formation to a definite orientation in vitro and in vivo. J Bone Miner Res 2002;17:1814-21.
40. Okazaki R, Ootsuyama A, Uchida S, Norimura T. Effects of a 4.7 T static magnetic field on fetal development in ICR mice. J Radiat Res 2001;42:273-83. (Pubitemid 33613205)
41. Zhang XY, Xue Y, Zhang Y. Effects of 0.4 T rotating magnetic field exposure on density, strength, calcium and metabolism of rat thigh bones. Bioelectromagnetics 2006;27:1-9.
42. Yan QC, Tomita N, Ikada Y. Effects of static magnetic field on bone formation of rat femurs. Med Eng Phys 1998;20:397-402.
43. Benglis D, Wang MY, Levi AD. A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery. Neurosurgery 2008;62(5 Suppl):423-31.
44. Wong DA, Kumar A, Jatana S, Ghiselli G, Wong K. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J 2008;8:1011-18.
45. Lepperdinger G, Brunauer R, Jamnig A, Laschober G, Kassem M. Controversial isue: is it safe to employ mesenchymal stem cells in cell-based therapies? Exp Gerontol 2008;43:1018-23.
46. Rayment EA, Williams DJ. Mind the gap: challenges in characteristing and quantifying cell- and tissue-based therapies for clinical translation. Stem Cells 2010;28:996-1004.
47. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid- resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:1579-86.
48. Müller I, Vaegler M, Holzwarth C, et al. Secretion of angiogenic proteins by human multipotent mesenchymal stromal cells and their clinical potential in the treatment of avascular osteonecrosis. Leukemia 2008;22:2054-61.